The importance of new antidepressants in the treatment of anxiety/depressive disorders
The importance of new antidepressants in the treatment of anxiety/depressive disorders
复制标题
DOI：
10.1055/s-2007-979217
复制
发表时间：
1999-07-01
影响因子：
4.3
通讯作者：
Möller, HJ
中科院分区：
文献类型：
--
作者：
Boerner, RJ;Möller, HJ
临床上经常见到患有焦虑症和抑郁症的患者。分别根据DSM-III/IV和ICD-10的诊断标准，可能存在各种症状和严重程度的组合。这些患者的症状可能从阈下焦虑或抑郁到焦虑和抑郁障碍的组合。除了对诊断问题和此类组合的流行病学发生率进行广泛调查外，还对药物治疗方法进行了严格审查。荟萃分析表明，各种血清素再摄取抑制剂（SSRI）的抗焦虑功效即使不是优于三环类抗抑郁药（TCA），也是相当的。因此，SSRI 可被视为一种治疗选择，尤其是因为其不良反应极少且耐受性良好。最近的抗抑郁药的抗焦虑功效正受到密切关注。西酞普兰、文拉法辛以及奈法唑酮（因其已确定的镇静作用）似乎特别适合填补可能的治疗空白，并为躁动患者提供 TCA 的替代方案。
Patients suffering from anxiety and depression are often seen in clinical practice. In accordance with the diagnostic criteria of DSM-III/IV and ICD-10, respectively, there may be various combinations of symptoms and degrees of severity. The symptoms of these patients may range from subthreshold anxiety or depression to a combination of anxiety and depressive disorders. Besides giving an extensive survey of diagnostic problems and the epidemiological incidence of such combinations, pharmacotherapeutic approaches are critically reviewed. Metaanalyses have shown that various serotonin reuptake inhibitors (SSRI) are equivalent, if not superior, to tricyclic antidepressants (TCA) in their anti-anxiety effectiveness. Hence, SSRI may be considered a therapy of choice, not least on account of very few adverse effects and good tolerance. More recent antidepressants are under scrutiny for their anti-anxiety efficacy. Citalopram, venlafaxine and, because of its established sedative action, nefazodone seem to be particularly suited to fill a possible therapeutic gap and to provide agitated patients with an alternative to TCA.